Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06628453 · ClinicalTrials.gov registry record · NA

CGM for Management of Type 2 Diabetes in Pregnancy

A NA study of Pregnancy and Type 2 Diabetes Mellitus (T2DM), sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
NA
Development phase
564
Enrollment target
7
Study locations

NCT06628453: Recruiting NA study of Pregnancy and Type 2 Diabetes Mellitus (T2DM), sponsored by University of Alabama at Birmingham.

NCT06628453 is a NA study of Pregnancy and Type 2 Diabetes Mellitus (T2DM) that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 564 participants, below the 870-participant average among 191 other Pregnancy trials with a reported enrollment target (35% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06628453, a NA study of Pregnancy and Type 2 Diabetes Mellitus (T2DM), is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
NA
Development phase
564 participants
Enrollment target
7
Study locations

Study Summary

The goal of this clinical trial is to learn if continuous glucose monitoring works better than self-monitoring of blood glucose (fingersticks) to treat type 2 diabetes in pregnancy. It will also learn about all risk factors (biologic, personal, social) for maternal and infant complications in type 2 diabetes pregnancies. The main questions it aims to answer are: 1. Does continuous glucose monitoring improve infant outcomes compared to self-monitoring of blood glucose? 2. Does continuous glucose monitoring improve maternal diabetes control and other maternal outcomes compared to self-monitoring of blood glucose? 3. What other factors increase the risk of maternal and infant complications? Participants will: 1. Use continuous glucose monitoring or self-monitoring of blood glucose to monitor blood sugar control from enrollment until delivery 2. Have blood drawn at enrollment, 24 weeks, 34 weeks and delivery to measure hemoglobin A1c levels and store blood for future analysis 3. Complete surveys about social support, environmental stressors, diabetes distress and glucose monitoring satisfaction at research visits 4. Have umbilical cord blood collected at delivery for analysis

Primary Outcome

Percentage of time spent within target range (63-140mg/dL) on Continuous Glucose Monitoring at 34 weeks gestation

Interventions

  • DEVICE CGM

Study Locations (7)

Alabama

  • University of Alabama at Birmingham - Birmingham

California

  • University of California at San Diego - San Diego

North Carolina

  • University of North Carolina - Chapel Hill - Chapel Hill

Oregon

  • Oregon Health and Science University - Portland

Pennsylvania

  • University of Pennsylvania - Philadelphia

South Carolina

  • Prisma Health Greenville Memorial Hospital - Greenville

Texas

  • University of Texas Health Science Center at Houston - Houston

Trial Details

FieldValue
Enrollment Target 564 participants
Start Date 2025-04-08
Est. Completion 2029-07
Phase NA
University of Alabama at Birmingham

1,160 total trials

What NCT06628453 shows while recruiting

NCT06628453 is an interventional study that assigns participants to a tested intervention. The registered 564 participants enrollment target is mid-sized for trials with a published cap, below the 870-participant average among 191 other Pregnancy trials with a reported enrollment target (35% lower).

The record links to 2 conditions, with Pregnancy appearing as the primary indexed condition, and to 1 intervention - of which CGM is the first listed.

NCT06628453 lists 7 locations in 7 states (Alabama, California, North Carolina).

Frequently Asked Questions

What is clinical trial NCT06628453 about?

NCT06628453 is a clinical study titled "CGM for Management of Type 2 Diabetes in Pregnancy". The goal of this clinical trial is to learn if continuous glucose monitoring works better than self-monitoring of blood glucose (fingersticks) to treat type 2 diabetes in pregnancy. It will also learn about all risk factors (biologic, personal, social) for maternal and infant complications in type 2...

What is the current status of trial NCT06628453?

This trial is currently recruiting. It is a NA study. The enrollment target is 564 participants. The study started on 2025-04-08. Estimated completion is 2029-07.

What conditions does trial NCT06628453 study?

This clinical trial studies the following conditions: Pregnancy, Type 2 Diabetes Mellitus (T2DM).

What interventions are being tested in trial NCT06628453?

The interventions under investigation include: CGM (DEVICE).

Who is sponsoring clinical trial NCT06628453?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06628453 being conducted?

This trial has 7 study locations across Alabama, California, North Carolina, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pregnancy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06628453's enrollment target sits among peer trials

564 44th of 191 higher than 148 of 191 other Pregnancy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pregnancy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06146725 · 564 participants

    The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)

  • NCT06188520 · 564 participants · Phase 1

    A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

  • NCT07125326 · 564 participants · NA

    How the Method of Bladder Emptying After Epidural Placement in Labor Affects Postpartum Voiding

  • NCT07007065 · 561 participants · Phase 3

    Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06628453, the US trial registry maintained by the National Library of Medicine. NCT06628453 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.